Insights into Tardive Dyskinesia and Chorea Treatment with Austedo and Austedo XR Reported at Psych Congress 2024

The majority of people with TD or chorea associated with Huntington disease (HD) who were treated with Austedo XR (deutetrabenazine; Teva Neuroscience, Kansas City, MO) reported a reduction in extra movement after treatment and satisfaction with the medication, according to real-world patient experience data presented at the Psych Congress 2024. Teva Pharmaceuticals also presented interim data from the phase 4 IMPACT-TD registry study, elucidating trends in the diagnosis of TD.

In the interim results of a noninterventional, prospective, cross-sectional survey, which included 131 participants treated with Austedo XR for TD or chorea associated with HD:

• 74% reported an improvement in extra movements with the medication.
• 76% reported that a reduction in their extra movements after treatment improved their comfort in social settings and their well-being.
• >50% reported that a reduction in their extra movements improved their physical health and work or school/life balance.
• 87% reported overall satisfaction with the medication, 98% reported that Austedo XR was easy to use and incorporate into daily routines, and 95% reported that they would continue to take the medication.

Additionally, IMPACT-TD is a 2-part, phase 4, 3-year longitudinal observational study evaluating TD progression over time and the condition’s impact on patients’ lives. In Part A, people with TD reported information about their experience with the condition. In Part B, clinician-reported outcomes related to treatment with once-daily Austedo and twice-daily Austedo XR were collected from 45 participating centers. Interim results of this study show that people with psychotic disorders (n=135) were less likely to receive a TD diagnosis (36%) compared with people with mood disorders (n=141; 50%), despite similarities in mean Abnormal Involuntary Movement Scale (AIMS) scores (8.7 vs 8.0) and impact of TD.